Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28726666 | 0.82 | TSHR (0.43) | TSHRHTR2ACA1CA2POLB | |
| SCHEMBL1675990 | 0.81 | EGFR (0.56) | TSHRHTR2APOLBKMT2ACYP1A2 | |
| SCHEMBL28754501 | 0.81 | GRM1 (0.42) | TSHRCYP1A2MAPTEGFR | |
| SCHEMBL28859675 | 0.79 | CYP1A2 (0.64) | TSHRCA2POLBKMT2ACYP1A2 | |
| SCHEMBL2108892 | 0.79 | TSHR (0.49) | TSHRHTR2ACA1CA2POLB | |
| SCHEMBL42370 | 0.76 | EGFR (0.51) | TSHRHTR2ACA1CA2KMT2A | |
| SCHEMBL1568272 | 0.76 | TSHR (0.50) | TSHRHTR2ACA1CA2POLB | |
| SCHEMBL13044481 | 0.75 | KMT2A (0.52) | HTR2ACA1CA2POLBKMT2A | |
| SCHEMBL8279094 | 0.75 | POLB (0.50) | TSHRHTR2ACA1CA2POLB | |
| SCHEMBL87862 | 0.75 | TSHR (0.49) | TSHRHTR2ACA1CA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000069878-A1 | UNIVERSAL SOLID SUPPORTS SUITABLE FOR THE SYNTHESIS OF NUCLEIC ACIDS | NGO NAM Q (US) | 2000-11-23 | — | — | WO | claimed |
| EP-3784262-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | F. Hoffmann-La Roche AG (CH) | 2021-03-03 | — | — | EP | disclosed |
| EP-3390396-A1 | ISOINDOLE COMPOUNDS | Astrazeneca AB (SE) | 2018-10-24 | — | — | EP | disclosed |
| EP-3368093-A1 | COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER | Pierre Fabre Medicament (FR) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017102784-A9 | ISOINDOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2018-04-05 | — | — | WO | disclosed |
| EP-3288593-A1 | CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER | Pierre Fabre Médicament (FR) | 2018-03-07 | — | — | EP | disclosed |
| WO-2017102784-A1 | ISOINDOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017072196-A1 | COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-05-04 | — | — | WO | disclosed |
| EP-3134125-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | Pierre Fabre Médicament (FR) | 2017-03-01 | — | — | EP | disclosed |
| EP-3134124-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | Pierre Fabre Médicament (FR) | 2017-03-01 | — | — | EP | disclosed |
| WO-2008048589-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF HCV | XTL BIOPHARMACEUTICALS LTD (US) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008036127-A2 | OLIGONUCLEOTIDE ANALOGS HAVING CATIONIC INTERSUBUNIT LINKAGES | AVI BIOPHARMA, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008007112-A1 | TETRAHYDROFURO [3, 2-B] PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| EP-1865989-A2 | PEG-POLY(ORTHO ESTER) GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS | AP Pharma, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007095443-A2 | GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING S.P.A. (IT) | 2007-08-23 | — | — | WO | disclosed |
| WO-2006105148-A2 | PEG-POLY(ORTHO ESTER) GRAFT COPOLYMERS AND PHARMACEUTICAL COMPOSITIONS | AP PHARMA, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006016787-A1 | CANTILEVER FOR ATOMIC FORCE MICROSCOPE, AND METHOD OF MEASURING BIOMOLECULE INTERACTION USING THE SAME | POSTECH FOUNDATION (KR) | 2006-02-16 | — | — | WO | disclosed |
| EP-1007699-A4 | PEPTIDE-ENHANCED TRANSFECTIONS | LIFE TECHNOLOGIES INC (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1007699-A1 | PEPTIDE-ENHANCED TRANSFECTIONS | Life Technologies, Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1998040502-A1 | PEPTIDE-ENHANCED TRANSFECTIONS | LIFE TECHNOLOGIES, INC. (US) | 1998-09-17 | — | — | WO | disclosed |